C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.040
+0.010 (0.33%)
At close: Mar 6, 2026, 4:00 PM EST
3.027
-0.013 (-0.44%)
After-hours: Mar 6, 2026, 7:14 PM EST
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover C4 Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $12.2, which forecasts a 301.32% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $30.
Price Target: $12.2 (+301.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for C4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +130.26% | Feb 27, 2026 |
| Brookline Capital | Brookline Capital | Strong Buy Maintains $20 → $30 | Strong Buy | Maintains | $20 → $30 | +886.84% | Feb 23, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $5 | Buy | Maintains | $10 → $5 | +64.47% | Dec 17, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +228.95% | Sep 23, 2025 |
Financial Forecast
Revenue This Year
22.98M
from 35.95M
Decreased by -36.08%
Revenue Next Year
22.98M
from 22.98M
EPS This Year
-1.25
from -1.27
EPS Next Year
-1.06
from -1.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 42.0M | 36.8M | |||
| Avg | 23.0M | 23.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.8% | 59.9% | |||
| Avg | -36.1% | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.82 | -0.71 | |||
| Avg | -1.25 | -1.06 | |||
| Low | -1.87 | -1.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.